Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 34

1.

Synthesis and SAR of Benzisothiazole- and Indolizine-β-d-glucopyranoside Inhibitors of SGLT2.

Zhou H, Danger DP, Dock ST, Hawley L, Roller SG, Smith CD, Handlon AL.

ACS Med Chem Lett. 2010 Jan 29;1(1):19-23. doi: 10.1021/ml900010b. eCollection 2010 Apr 8.

PMID:
24900169
[PubMed]
Free PMC Article
2.

Patient considerations in the management of type 2 diabetes - critical appraisal of dapagliflozin.

Salvo MC, Brooks AD, Thacker SM.

Patient Prefer Adherence. 2014 Apr 22;8:493-502. doi: 10.2147/PPA.S59169. eCollection 2014. Review.

PMID:
24790417
[PubMed]
Free PMC Article
3.

The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials.

Sun YN, Zhou Y, Chen X, Che WS, Leung SW.

BMJ Open. 2014 Apr 7;4(4):e004619. doi: 10.1136/bmjopen-2013-004619.

PMID:
24710132
[PubMed]
Free PMC Article
4.

Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.

Sasaki T, Seino Y, Fukatsu A, Sakai S, Samukawa Y.

Adv Ther. 2014 Mar;31(3):345-61. doi: 10.1007/s12325-014-0102-3. Epub 2014 Feb 18.

PMID:
24535625
[PubMed - in process]
Free PMC Article
5.

Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.

Reilly TP, Graziano MJ, Janovitz EB, Dorr TE, Fairchild C, Lee F, Chen J, Wong T, Whaley JM, Tirmenstein M.

Diabetes Ther. 2014 Jun;5(1):73-96. doi: 10.1007/s13300-014-0053-3. Epub 2014 Jan 29.

PMID:
24474422
[PubMed]
Free PMC Article
6.
7.

Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus.

Bays H.

Diabetes Ther. 2013 Dec;4(2):195-220. doi: 10.1007/s13300-013-0042-y. Epub 2013 Oct 19.

PMID:
24142577
[PubMed]
Free PMC Article
8.

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.

Kohan DE, Fioretto P, Tang W, List JF.

Kidney Int. 2014 Apr;85(4):962-71. doi: 10.1038/ki.2013.356. Epub 2013 Sep 25.

PMID:
24067431
[PubMed - in process]
Free PMC Article
9.

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition.

Poudel RR.

Indian J Endocrinol Metab. 2013 Jul;17(4):588-93. doi: 10.4103/2230-8210.113725.

PMID:
23961473
[PubMed]
Free PMC Article
10.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus.

Heise T, Seman L, Macha S, Jones P, Marquart A, Pinnetti S, Woerle HJ, Dugi K.

Diabetes Ther. 2013 Dec;4(2):331-45. doi: 10.1007/s13300-013-0030-2. Epub 2013 Jul 10.

PMID:
23838841
[PubMed]
Free PMC Article
11.

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study.

Inagaki N, Kondo K, Yoshinari T, Maruyama N, Susuta Y, Kuki H.

Diabetes Obes Metab. 2013 Dec;15(12):1136-45. doi: 10.1111/dom.12149. Epub 2013 Jul 14.

PMID:
23782594
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

SGLT5 reabsorbs fructose in the kidney but its deficiency paradoxically exacerbates hepatic steatosis induced by fructose.

Fukuzawa T, Fukazawa M, Ueda O, Shimada H, Kito A, Kakefuda M, Kawase Y, Wada NA, Goto C, Fukushima N, Jishage K, Honda K, King GL, Kawabe Y.

PLoS One. 2013;8(2):e56681. doi: 10.1371/journal.pone.0056681. Epub 2013 Feb 25.

PMID:
23451068
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.

Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF.

BMC Med. 2013 Feb 20;11:43. doi: 10.1186/1741-7015-11-43. Erratum in: BMC Med. 2013;11:193.

PMID:
23425012
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

A review of the efficacy and safety of oral antidiabetic drugs.

Stein SA, Lamos EM, Davis SN.

Expert Opin Drug Saf. 2013 Mar;12(2):153-75. doi: 10.1517/14740338.2013.752813. Epub 2012 Dec 14. Review.

PMID:
23241069
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.

Clar C, Gill JA, Court R, Waugh N.

BMJ Open. 2012 Oct 18;2(5). pii: e001007. doi: 10.1136/bmjopen-2012-001007. Print 2012.

PMID:
23087012
[PubMed]
Free PMC Article
16.

Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes.

Kim Y, Babu AR.

Diabetes Metab Syndr Obes. 2012;5:313-27. doi: 10.2147/DMSO.S22545. Epub 2012 Aug 31.

PMID:
22977310
[PubMed]
Free PMC Article
17.

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.

Whaley JM, Tirmenstein M, Reilly TP, Poucher SM, Saye J, Parikh S, List JF.

Diabetes Metab Syndr Obes. 2012;5:135-48. doi: 10.2147/DMSO.S22503. Epub 2012 Jul 23.

PMID:
22923998
[PubMed]
Free PMC Article
18.

Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?

Liu JJ, Lee T, DeFronzo RA.

Diabetes. 2012 Sep;61(9):2199-204. doi: 10.2337/db12-0052.

PMID:
22923645
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.

Zambrowicz B, Freiman J, Brown PM, Frazier KS, Turnage A, Bronner J, Ruff D, Shadoan M, Banks P, Mseeh F, Rawlins DB, Goodwin NC, Mabon R, Harrison BA, Wilson A, Sands A, Powell DR.

Clin Pharmacol Ther. 2012 Aug;92(2):158-69. doi: 10.1038/clpt.2012.58. Epub 2012 Jul 4.

PMID:
22739142
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes.

Chao EC.

Core Evid. 2012;7:21-8. doi: 10.2147/CE.S16359. Epub 2012 Jun 1.

PMID:
22701099
[PubMed]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk